IP Library Granted Patent US 10,738,088
Granted Patent B2
US 10,738,088 · App. 16/054,327 · Granted Aug 11, 2020

Non-naturally occurring porcine reproductive and respiratory syndrome virus (PRRSV) and methods of using

Inventors: Hiep Lai Xuan Vu (Lincoln, NE); Fernando Osorio (Lincoln, NE); William W. Laegreid (Laramie, WY); Asit K. Pattnaik (Lincoln, NE); Fangrui Ma (Lincoln, NE)
Assignees: NUtech Ventures; The Board of Trustees of the University of Illinois
C07K14/005A61K39/12C12N7/00A61K2039/552C12N2770/10021C12N2770/10022C12N2770/10034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,738,088
App. No.
16/054,327
Granted
Aug 11, 2020
Kind
B2
Abstract

A non-naturally occurring porcine reproductive and respiratory syndrome virus (PRRSV) is provided herein, and methods of making and using the non-naturally occurring PRRSV also are provided.

Claims (17)

1. A non-structural PRRSV-CON polypeptide having a sequence selected from the group consisting of SEQ ID NO:3, 5, and 7.

2. The polypeptide of claim 1 , wherein the polypeptide is encoded by a nucleic acid, respectively, having a sequence selected from the group consisting of SEQ ID NO:2, 4, and 6.

3. A virus particle comprising the non-structural PPRSV-CON polypeptide of claim 1 .

4. A composition comprising the virus particle of claim 3 and a pharmaceutically acceptable carrier.

5. The composition of claim 4 , further comprising an adjuvant.

6. A composition comprising the non-structural polypeptide of claim 1 and a pharmaceutically acceptable carrier.

7. The composition of claim 6 , further comprising an adjuvant.

8. A method for eliciting an immune response to PPRSV in a porcine, comprising administering, to a porcine:

(i) an effective amount of the polypeptide of claim 1 ;

(ii) an effective amount of the virus particle of claim 3 ; or

(iii) an effective amount of the composition of claim 6 .

9. The method of claim 8 , wherein the administration is selected from the group consisting of intramuscularly, intraperitoneally, and orally.

10. A method for treating or preventing PPRS in a porcine, comprising administering, to a porcine:

(i) an effective amount of the polypeptide of claim 1 ;

(ii) an effective amount of the virus particle of claim 3 ; or

(iii) an effective amount of the composition of claim 6 .

11. The method of claim 10 , wherein the administration is selected from the group consisting of intramuscularly, intraperitoneally, and orally.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 052841 FRAME: 0489. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Nov 10, 2021
From: XUAN VU, HIEP LAI; OSORIO, FERNANDO; PATTNAIK, ASIT K.; MA, FANGRUI
To: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
Reel/Frame 058084/0486 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2020
From: VU, HIEP LAI; OSORIO, FERNANDO; PATTNAIK, ASIT K.; MA, FANGRUI
To: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
Reel/Frame 052841/0489 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2020
From: LAEGREID, WILLIAM W.
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Reel/Frame 052841/0623 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2020
From: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
To: NUTECH VENTURES
Reel/Frame 052841/0966 →
Continuity (3)
Continuation 15127931
Provisional Application 61968465 · Mar 21, 2014
Related Publication 20190048042A1 · Feb 14, 2019